SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, quantitative RT-PCR of CP-CML LSC from both a murine model and primary patient samples, and immunohistochemistry/immunofluorescence of primary human BM samples provide robust evidence for Hh pathway de-regulation in CP-CML and a rationale for exploring the efficacy of the clinically relevant SMO antagonist LDE225 as a Hh pathway inhibitor in CP-CML.